Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiagnostykaFRA:7JS +2.13%18 EV-to-EBIT is 17.80 as of Jul. 21, 2026, which is 0% below its 10-year median of 17.81. GuruFocus rates FRA:7JS with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 104 Medical Diagnostics & Research companies, Diagnostyka ranks better than 62.5% on this metric.
The historical rank and industry rank for Diagnostyka's EV-to-EBIT or its related term are showing as below:
FRA:7JS'
s EV-to-EBIT Range Over the Past 10 Years
Min: 14.99 Med: 17.81 Max: 21.8
Current: 17.48
During the past 5 years, the highest EV-to-EBIT of Diagnostyka was 21.80. The lowest was 14.99. And the median was 17.81.
FRA:7JS's EV-to-EBIT is ranked better than 62.5% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.7
vs FRA:7JS: 17.48
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Diagnostyka's Enterprise Value for the quarter that ended in Mar. 2026 was €1,570.2 Mil.
Diagnostyka's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €90.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnostyka EV-to-EBIT Related Terms
Diagnostyka EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Diagnostyka's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Diagnostyka's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnostyka EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnostyka's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Diagnostyka's EV-to-EBIT falls into.
Diagnostyka's current Enterprise Value is €1,618.6 Mil.
Diagnostyka's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €90.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnostyka (FRA:7JS) has a EV-to-EBIT of 17.80 as of Jul. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Diagnostyka and its competitors. This is near median its historical median of 17.81. Over the past decade, Diagnostyka's EV-to-EBIT has ranged from 14.99 to 21.80. According to the industry distribution chart, Diagnostyka ranks #39 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 37.5%.
Is Diagnostyka's EV-to-EBIT too high?
Diagnostyka's current EV-to-EBIT of 17.80 is near median its 10-year median of 17.81. Over the past 10 years, this metric has ranged from a low of 14.99 to a high of 21.80. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.70. Diagnostyka's value of 17.80 is 21.6% below this industry median. Based on the distribution chart, Diagnostyka ranks #39 out of 104 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diagnostyka has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Diagnostyka's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnostyka ranks #39 out of 104 companies for EV-to-EBIT. This puts Diagnostyka in the upper half of its industry. The industry median EV-to-EBIT is 22.70. Diagnostyka's value of 17.80 is 21.6% below this benchmark. Historically, Diagnostyka's own EV-to-EBIT has ranged from 14.99 to 21.80 over the past decade. While the company's 10-year median is 17.81 vs. the industry median of 22.70, Diagnostyka has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.70, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnostyka's current EV-to-EBIT of 17.80 is 21.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Diagnostyka and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnostyka's current EV-to-EBIT is 17.80, which is near median its own 10-year median of 17.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostyka stock overvalued right now?
Diagnostyka (FRA:7JS) has a current EV-to-EBIT of 17.80. The current EV-to-EBIT is 17.80, which is near median its 10-year median of 17.81 and 21.6% below the Medical Diagnostics & Research industry median of 22.70. Diagnostyka's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Diagnostyka (FRA:7JS), the current EV-to-EBIT is 17.80 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
18GF Score
Get the complete analysis for FRA:7JS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7JS has been successfully added to your 
